-
Nov 19 |
Diagnostics World | A team of researchers from Institute of Science Tokyo, Japan, are using nanowires with machine learning analysis to detect cancer-associated miRNAs in urine. Their research findings were published last month online in Analytical Chemistry.
More
-
Nov 15 |
Diagnostics World | Placental pathology has potential to reveal critical insights into pregnancy complications, yet it remains underutilized in clinical trials. By incorporating placental evaluations into clinical research, doctors could better understand and treat conditions like preeclampsia and preterm birth, which are currently diagnosed based only on clinical signs.
More
-
Nov 13 |
Diagnostics World | Researchers in Israel recently showcased a novel platform that can be used in the future for the early diagnosis of Parkinson’s disease (PD) by quantifying the distribution of alpha-synuclein (α-syn) in skin biopsies. A proof-of-concept study in humans, supported in part by the Michael J. Fox Foundation, suggests the single-molecule-level detection method might enable the disease to be detected up to 20 years before the first motor symptoms appear.
More
-
Nov 12 |
Diagnostics World | Recent years have seen progress toward developing tools that are designed to analyze a human breath sample to detect, diagnose, or monitor various health issues. Some of these efforts have focused on combating deadly infectious diseases, with intentions of creating cost-effective, easy-to-use breathalyzers capable of being deployed in rural, remote, and low-resource settings.
More
-
Nov 07 |
Diagnostics World | A next-generation liquid biopsy approach combining cell-free DNA (cfDNA) “fragmentome” and protein biomarker analyses could aid in the early detection of ovarian cancer, suggests a recent study by researchers in the U.S., The Netherlands, and Denmark. The DELFI-Pro classifier was found to have a high positive predictive value, a key accuracy metric.
More
-
Nov 04 |
Diagnostics World | A diagnostic test invented at the University of Arizona has demonstrated its potential to predict the likelihood of relapse or recurrence among patients with early-stage breast cancer and their response to antifibrotic therapy. The tool, known as MeCo Score, measures metastatic risk based on the acclimation of cancer cells to the mechanical stiffness of tissue (fibrosis) as computed from RNA sequencing data on tumor samples.
More
-
Oct 31 |
Diagnostics World | In another few years, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) analytes may be “obsolete” because the famously bad and good guys in standard cholesterol tests provide less useful information about heart health than other lipid molecules circulating in the blood. The evidence emerges from a recent study in children and adolescents with overweight or obesity finding a new relationship between lipids and diseases impacting metabolism.
More
-
Oct 30 |
Diagnostics World | Revvity launches the in vitro diagnostic EURORealTime APOE assay in European countries that accept the CE mark; Withings Health Solutions announces a first-of-its-kind cellular blood pressure monitor; and more.
More
-
Oct 29 |
Diagnostics World | Cytovale plans to commercially expand IntelliSep, the company’s sepsis diagnostic test, to more hospital emergency departments and health systems nationwide; C2N Diagnostics will continue to develop their next-generation tests specific to tau tangle pathology; and more.
More
-
Oct 25 |
Diagnostics World | Owkin and AstraZeneca announced a new partnership this month to develop an AI-powered tool to pre-screen for germline BRCA (gBRCA) mutations in breast cancer directly from digitized pathology slides. As part of Owkin’s ongoing collaboration with Gustave Roussy and The Centre Léon Bérard through PortrAIt, a French consortium to accelerate precision medicine through AI-enabled digital pathology, this tool aims to significantly accelerate and expand access to gBRCA testing that too many patients may not be considered for.
More
-
Nov 20 |
More
-
Nov 20 |
PathAI, a global leader in AI-powered digital pathology solutions and the developer of the market-leading AISight1 Image Management System (IMS), today announced the integration of several AI products from market leading digital pathology companies, including Deep Bio, DoMore Diagnostics, Paige, and Visiopharm. Through these collaborations, PathAI will provide algorithms from these developers directly within its AISight IMS, reinforcing its commitment to offering the most versatile, reliable, and interoperable IMS on the market.
More
-
Nov 20 |
The MiSeq i100 Series of sequencing equipment was introduced by Illumina, a multinational corporation dedicated to DNA sequencing and array-based technologies. The new systems are designed to improve next-generation sequencing (NGS) capabilities for labs by providing quick turnaround and user-friendliness.
More
-
Nov 19 |
Owkin’s MSIntuit® CRC v2, a next-generation AI diagnostic aimed at transforming the detection and treatment of colorectal cancer, will be integrated into Proscia’s Concentriq® software platform, making it available as part of Proscia’s precision medicine AI portfolio.
More
-
Nov 19 |
Sakura Finetek Europe and MEDIPATH announced their collaboration to enhance cancer diagnostics and thus contribute to improved patient therapeutic management.
More
-
Nov 18 |
City Therapeutics, which uses next-generation engineering of small interfering RNAs (siRNAs) to drive improvements in RNA interference (RNAi)--based therapeutics, has announced its debut along with a $135 million Series A funding.
More
-
Nov 15 |
Coronado Research announced today that Alexander McCormick has been appointed as Chief Commercial Officer.
More
-
Nov 14 |
• Augurex launches Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs), supporting the development of a first-in-class diagnostic test for axial spondyloarthritis (axSpA) by New Day Diagnostics.
• The new laboratory developed test, which uses Anti-14-3-3eta Multiplex ASRs as components, aims to reduce the extensive diagnostic delay typically experienced by axSpA patients, provide clinicians with a reliable tool to help improve patient outcomes, and potentially aid the early diagnosis and treatment of axSpA.
More
-
Nov 14 |
AMP announced a joint consensus report with APHL that describes best practices and offers key pre-analytical, analytical, and post-analytical considerations to help improve critical NGS-based surveillance programs.
More
-
Nov 13 |
Partnership expands Gifthealth’s presence to cover 25% of gastroenterologists nationally.
More
View more articles